To read the full story, subscribe or sign in.

Round two for former Pharmasset execs with HBV start-up Oncore

Oct. 1, 2014

After operating off the grid for nearly two years, Oncore Biopharma Inc. has unveiled three recent deals to mark its presence in the hepatitis B virus (HBV) space in a big way.

BioWorld

Today's news in brief

BioWorld

BioWorld briefs for April 9, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for April 9, 2025.

Approved label with medical icons, professional

FDA clears path for Boston Sci’s Bolt IVL to challenge J&J’s Shockwave

BioWorld MedTech

Boston Scientific Corp.’s up to $664 million acquisition of Bolt Medical Inc. closed just days after Bolt secured U.S. FDA 520(k) clearance for its intravascular...

Caution tape displaying US flag, tariffs

Biopharma exempt from US reciprocal tariffs, but not untouched

BioWorld

At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald...

Remegen’s lupus drug surfaces with phase III myasthenia gravis data

BioWorld

Remegen Co. Ltd. emerged as a surprise challenger in the generalized myasthenia gravis space, unveiling positive phase III data of its China-approved lupus drug,...